newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare